Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research report on Thursday, November 14th.

Trevena Price Performance

Shares of TRVN stock opened at $1.76 on Friday. The business has a 50-day moving average of $1.80 and a 200 day moving average of $4.07. Trevena has a 1-year low of $1.13 and a 1-year high of $19.23. The stock has a market capitalization of $1.52 million, a PE ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The firm had revenue of $0.28 million during the quarter. Analysts anticipate that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.